TCR therapy (T-cell receptor engineered T cells)

TCR therapy engineers a patient’s T cells with a high-affinity T-cell receptor (TCR) that recognises an intracellular tumour peptide presented on HLA — a target class that CAR-T (which sees surface antigens) cannot reach. Adaptimmune’s Tecelra (afamitresgene autoleucel) was the first TCR-T approved, targeting MAGE-A4 in synovial sarcoma, and Immunocore’s Kimmtrak (tebentafusp), a soluble TCR-bispecific against gp100, was shown in April 2026 to double the likelihood of being alive at five years in metastatic uveal melanoma. Lyell Immunopharma reported a June 2026 safety update on LYL273 in relapsed solid tumours, TScan Therapeutics is building a TCR-T discovery and treatment platform (Nasdaq: TCRX, Q1 2026), and Medigene’s MDG1015 is a first-in-class, third-generation TCR construct. The field is the engineered-T-cell answer to solid tumours.

The key directions of TCR therapy are:

1. Autologous TCR-T cell therapy (TCR-T): patient T cells transduced with an affinity-enhanced TCR against an intracellular peptide-MHC target — Adaptimmune (Tecelra, MAGE-A4), Lyell (LYL273), TScan, Medigene (MDG1015).
2. Soluble TCR bispecifics (TCR Bispecific): a fused TCR-anti-CD3 molecule that recruits polyclonal T cells to a tumour peptide-MHC — Immunocore (Kimmtrak/tebentafusp, gp100).
3. TCR discovery and target selection (TCR Discovery): high-throughput identification of tumour-specific peptide-MHC targets (MAGE-A4, NY-ESO-1, gp100, PRAME) and of high-affinity, HLA-restricted TCRs (e.g. HLA-A*02:01).
4. Solid-tumour durability and manufacturing (Solid Tumour): epigenetic reprogramming to resist T-cell exhaustion (Lyell) and point-of-care manufacturing to shorten vein-to-vein time.

Sectoral value chain#

[tumour peptide-MHC target] ──> [high-affinity TCR isolation + lentiviral vector] ──> [engineered TCR-T product]
                                              │
                                     (lymphodepletion conditioning)
                                              │
                                              ▼
[solid-tumour response] <─── [TCR-T infusion + immune management] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• HLA-restricted peptide-MHC targeting (MHC Restriction): TCRs recognise intracellular peptides presented on HLA (e.g. HLA-A*02:01), which is what lets TCR therapy reach solid-tumour targets CAR-T cannot, but also ties each product to a patient’s HLA type.
• Lentiviral TCR delivery (Lentiviral Vector): TCR alpha and beta chains are delivered via integrating lentiviral vector, with engineered cysteine modifications to enforce correct pairing and avoid mis-pairing with the endogenous TCR.
• Soluble TCR bispecifics (TCR Bispecific): Immunocore’s Kimmtrak fuses an affinity-enhanced TCR to an anti-CD3 scFv, turning the TCR into an off-the-shelf drug that recruits polyclonal T cells.

The stack pairs high-affinity TCR discovery with chain-engineered lentiviral delivery, autologous GMP manufacturing, and — for the bispecific variant — a soluble TCR that recruits polyclonal T cells.

1. Autologous TCR-T (TCR-T):
   • Adaptimmune’s Tecelra (afamitresgene autoleucel) is the first approved TCR-T, targeting MAGE-A4 in synovial sarcoma; Lyell’s LYL273 (June 2026 safety update) and Medigene’s MDG1015 (third-generation TCR) extend the autologous class.
   • Lyell’s epigenetic reprogramming directly addresses T-cell exhaustion, the central reason engineered T cells fail in solid tumours.
2. Soluble TCR bispecifics (TCR Bispecific):
   • Immunocore’s Kimmtrak (tebentafusp) fuses an affinity-enhanced gp100 TCR to an anti-CD3 scFv, and was shown in April 2026 to double five-year survival in HLA-A*02:01+ metastatic uveal melanoma.
   • The bispecific format converts the TCR from a cell-bound receptor into an off-the-shelf drug that redirects the patient’s existing T cells.
3. TCR discovery and targeting (TCR Discovery):
   • TScan Therapeutics uses T-cell receptor sequencing to identify tumour-specific peptide-MHC targets and the TCRs that recognise them, feeding a pipeline across MAGE-A4, NY-ESO-1, gp100 and PRAME.
   • HLA restriction (e.g. HLA-A*02:01) is the defining constraint — and the opportunity — that lets TCR therapy reach intracellular tumour antigens.